Bexsero, egy új, meningococcus elleni vakcina

Translated title of the contribution: Bexsero, a novel vaccine against meningococcus

A. Lakos, Torzsa Péter, Ferenci Tamás

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Meningococcus B is the most prevalent Neisseria meningitidis serogroup isolated in Hungary. Bexsero is one of the vaccines developed against it, which has been available in Hungary since the summer of 2014. The authors summarize the most important issues and open questions concerning the disease and the vaccine based on literature review. Based on immunological evidence, it is expected that Bexsero provides protection against this rare but very serious infection. However, the vaccine is extremely expensive, the clinical effectiveness has not yet been proven and it frequently causes fever, especially in infants where the vaccine is most needed. According to the opinion of the authors, the formulation of a Hungarian guideline concerning the application of Bexsero should be postponed until the accumulating international experience makes it possible to better judge the vaccine's benefits, risks and cost-effectiveness. For patients with asplenia, complement defect or other immunological defect, or in case of markedly increased individual risk of contracting the disease, the vaccination is already justified.

Original languageHungarian
Pages (from-to)242-246
Number of pages5
JournalOrvosi Hetilap
Volume157
Issue number7
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

Neisseria meningitidis
Vaccines
Hungary
Cost-Benefit Analysis
Vaccination
Fever
4CMenB vaccine
Guidelines
Infection

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bexsero, egy új, meningococcus elleni vakcina. / Lakos, A.; Péter, Torzsa; Tamás, Ferenci.

In: Orvosi Hetilap, Vol. 157, No. 7, 01.02.2016, p. 242-246.

Research output: Contribution to journalArticle

Lakos, A. ; Péter, Torzsa ; Tamás, Ferenci. / Bexsero, egy új, meningococcus elleni vakcina. In: Orvosi Hetilap. 2016 ; Vol. 157, No. 7. pp. 242-246.
@article{9e64556156894627b6b7a89ef98ae10e,
title = "Bexsero, egy {\'u}j, meningococcus elleni vakcina",
abstract = "Meningococcus B is the most prevalent Neisseria meningitidis serogroup isolated in Hungary. Bexsero is one of the vaccines developed against it, which has been available in Hungary since the summer of 2014. The authors summarize the most important issues and open questions concerning the disease and the vaccine based on literature review. Based on immunological evidence, it is expected that Bexsero provides protection against this rare but very serious infection. However, the vaccine is extremely expensive, the clinical effectiveness has not yet been proven and it frequently causes fever, especially in infants where the vaccine is most needed. According to the opinion of the authors, the formulation of a Hungarian guideline concerning the application of Bexsero should be postponed until the accumulating international experience makes it possible to better judge the vaccine's benefits, risks and cost-effectiveness. For patients with asplenia, complement defect or other immunological defect, or in case of markedly increased individual risk of contracting the disease, the vaccination is already justified.",
keywords = "Bexsero, Clinical effectiveness, Cost-effectiveness, Meningococcal B vaccine, Side effects",
author = "A. Lakos and Torzsa P{\'e}ter and Ferenci Tam{\'a}s",
year = "2016",
month = "2",
day = "1",
doi = "10.1556/650.2016.30333",
language = "Hungarian",
volume = "157",
pages = "242--246",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "7",

}

TY - JOUR

T1 - Bexsero, egy új, meningococcus elleni vakcina

AU - Lakos, A.

AU - Péter, Torzsa

AU - Tamás, Ferenci

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Meningococcus B is the most prevalent Neisseria meningitidis serogroup isolated in Hungary. Bexsero is one of the vaccines developed against it, which has been available in Hungary since the summer of 2014. The authors summarize the most important issues and open questions concerning the disease and the vaccine based on literature review. Based on immunological evidence, it is expected that Bexsero provides protection against this rare but very serious infection. However, the vaccine is extremely expensive, the clinical effectiveness has not yet been proven and it frequently causes fever, especially in infants where the vaccine is most needed. According to the opinion of the authors, the formulation of a Hungarian guideline concerning the application of Bexsero should be postponed until the accumulating international experience makes it possible to better judge the vaccine's benefits, risks and cost-effectiveness. For patients with asplenia, complement defect or other immunological defect, or in case of markedly increased individual risk of contracting the disease, the vaccination is already justified.

AB - Meningococcus B is the most prevalent Neisseria meningitidis serogroup isolated in Hungary. Bexsero is one of the vaccines developed against it, which has been available in Hungary since the summer of 2014. The authors summarize the most important issues and open questions concerning the disease and the vaccine based on literature review. Based on immunological evidence, it is expected that Bexsero provides protection against this rare but very serious infection. However, the vaccine is extremely expensive, the clinical effectiveness has not yet been proven and it frequently causes fever, especially in infants where the vaccine is most needed. According to the opinion of the authors, the formulation of a Hungarian guideline concerning the application of Bexsero should be postponed until the accumulating international experience makes it possible to better judge the vaccine's benefits, risks and cost-effectiveness. For patients with asplenia, complement defect or other immunological defect, or in case of markedly increased individual risk of contracting the disease, the vaccination is already justified.

KW - Bexsero

KW - Clinical effectiveness

KW - Cost-effectiveness

KW - Meningococcal B vaccine

KW - Side effects

UR - http://www.scopus.com/inward/record.url?scp=84957893465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957893465&partnerID=8YFLogxK

U2 - 10.1556/650.2016.30333

DO - 10.1556/650.2016.30333

M3 - Article

C2 - 26853725

AN - SCOPUS:84957893465

VL - 157

SP - 242

EP - 246

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 7

ER -